189 related articles for article (PubMed ID: 31730602)
1. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Galinsky I; Coleman M; Fechter L
Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
[TBL] [Abstract][Full Text] [Related]
2. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Sly N; Gaspar K
Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
[TBL] [Abstract][Full Text] [Related]
3. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
5. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Stone RM; Manley PW; Larson RA; Capdeville R
Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin: First Global Approval.
Kim ES
Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
[TBL] [Abstract][Full Text] [Related]
7. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
Schlenk RF; Kayser S
Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
[TBL] [Abstract][Full Text] [Related]
12. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
13. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Tollkuci E
J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
16. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
[TBL] [Abstract][Full Text] [Related]
18. Updated safety of midostaurin plus chemotherapy in newly diagnosed
Roboz GJ; Strickland SA; Litzow MR; Dalovisio A; Perl AE; Bonifacio G; Haines K; Barbera A; Purkayastha D; Sweet K
Leuk Lymphoma; 2020 Dec; 61(13):3146-3153. PubMed ID: 32812818
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin approved for FLT3-mutated AML.
Levis M
Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
